D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342
Roy S. Herbst,Karen Kelly,Kari Chansky,Philip C. Mack,Wilbur A. Franklin,Fred R. Hirsch,James N. Atkins,Shaker R. Dakhil,Kathy S. Albain,Edward S. Kim,Mary W. Redman,John Crowley,David R. Gandara +12 more
TL;DR: Although both regimens met the efficacy criterion for continued evaluation, the concurrent regimen of paclitaxel/carboplatin plus cetuximab was chosen.
Journal ArticleDOI
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Ming-Sound Tsao,Akira Sakurada,Keyue Ding,Sarit Aviel-Ronen,Olga Ludkovski,Ni Liu,Aurélie Le Maître,David R. Gandara,David H. Johnson,James R. Rigas,Lesley Seymour,Frances A. Shepherd +11 more
TL;DR: Trends toward longer survival and a greater benefit from chemotherapy were observed in patients with exon 19/21 mutations and high EGFR copy, although the differences were not statistically significant.
Journal ArticleDOI
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment.
David R. Gandara,Denise R. Aberle,Derick H Lau,James R. Jett,Tim Akhurst,James L. Mulshine,Christine D. Berg,Edward F. Patz +7 more
TL;DR: Current data regarding the radiographic imaging ofBronchioloalveolar carcinoma is reviewed: its radiographic presentations in asymptomatic early-stage and in advanced-stage disease, the functional imaging characteristics of BAC, and challenges of response assessment, including evolving opportunities for computer-assisted image analysis.
Journal ArticleDOI
Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors
Benjamin K. Tomlinson,Jim Thomson,John S. Bomalaski,Monica Diaz,Taiwo Akande,Nichole Mahaffey,Tianhong Li,Mrinal Dutia,Karen Kelly,I-Yeh Gong,Thomas J. Semrad,David R. Gandara,Chong-Xian Pan,Primo N. Lara +13 more
TL;DR: ADI-PEG 20 demonstrated reasonable toxicity in combination with docetaxel in patients with advanced solid malignancies, and expansion cohorts are now accruing for both castrate-resistant prostate cancer and non–small cell lung cancer at a recommended phase II dose.
Journal ArticleDOI
Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry.
Suzanne Miyamoto,Sandra L. Taylor,Dinesh Kumar Barupal,Dinesh Kumar Barupal,Ayumu Taguchi,Gert Wohlgemuth,William R. Wikoff,Ken Y. Yoneda,David R. Gandara,Samir M. Hanash,Kyoungmi Kim,Oliver Fiehn,Oliver Fiehn +12 more
TL;DR: Results from two separate studies using gas chromatography time-of-flight mass spectrometry to profile metabolites in human blood samples that significantly differ from non-small cell lung cancer (NSCLC) adenocarcinoma and other lung cancer cases are reported.